{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:14:29Z","timestamp":1774476869671,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.expneurol.2012.05.015","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T23:21:10Z","timestamp":1339543270000},"page":"78-89","source":"Crossref","is-referenced-by-count":13,"title":["Tissue transglutaminase overexpression does not modify the disease phenotype of the R6\/2 mouse model of Huntington's disease"],"prefix":"10.1016","volume":"237","author":[{"given":"Ashish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kneynsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Tucholski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"van Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Detloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Lesort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2012.05.015_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1471-4159.2004.02839.x","article-title":"Tissue transglutaminase contributes to disease progression in the R6\/2 Huntington's disease mouse model via aggregate-independent mechanisms","volume":"92","author":"Bailey","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neurobiolaging.2005.04.001","article-title":"The protective effects of cystamine in the R6\/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase","volume":"27","author":"Bailey","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0197-4580(94)90132-5","article-title":"Huntington's disease, energy, and excitotoxicity","volume":"15","author":"Beal","year":"1994","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0959-4388(96)80100-0","article-title":"Mitochondria, free radicals, and neurodegeneration","volume":"6","author":"Beal","year":"1996","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0025","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbrc.2004.08.035","article-title":"Deranged neuronal calcium signaling and Huntington disease","volume":"322","author":"Bezprozvanny","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1471-4159.2010.06874.x","article-title":"Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases","volume":"114","author":"Bousquet","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jnr.1244","article-title":"NMDA receptor function in mouse models of Huntington disease","volume":"66","author":"Cepeda","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","article-title":"Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release","volume":"13","author":"Choo","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1083\/jcb.153.1.25","article-title":"Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates","volume":"153","author":"Chun","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1471-4159.1997.69010431.x","article-title":"Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG\/poly-Q neurodegenerative diseases?","volume":"69","author":"Cooper","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0060","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0065","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0896-6273(95)90346-1","article-title":"Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons","volume":"14","author":"DiFiglia","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0070","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0075","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2006.11.003","article-title":"N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease","volume":"81","author":"Fan","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0080","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0085","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1096\/fj.07-097709","article-title":"Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling","volume":"22","author":"Filiano","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nbd.2010.04.018","article-title":"Transglutaminase 2 protects against ischemic stroke","volume":"39","author":"Filiano","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0361-9230(01)00577-9","article-title":"Polyglutamine expansion neurodegenerative disease","volume":"56","author":"Fischbeck","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/abbi.1998.0592","article-title":"Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases","volume":"352","author":"Gentile","year":"1998","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0105","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0092-8674(93)90718-6","article-title":"Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism","volume":"74","author":"Green","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0110","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1096\/fasebj.5.15.1683845","article-title":"Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues","volume":"5","author":"Greenberg","year":"1991","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","article-title":"Mitochondrial defect in Huntington's disease caudate nucleus","volume":"39","author":"Gu","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0361-9230(03)00185-0","article-title":"Standardization and statistical approaches to therapeutic trials in the R6\/2 mouse","volume":"61","author":"Hockly","year":"2003","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1152\/physrev.00044.2008","article-title":"Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders","volume":"89","author":"Iismaa","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1471-4159.2001.00673.x","article-title":"N(epsilon)-(gamma-l-glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease","volume":"79","author":"Jeitner","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.bcp.2004.12.011","article-title":"Mechanism for the inhibition of transglutaminase 2 by cystamine","volume":"69","author":"Jeitner","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1471-4159.2008.05350.x","article-title":"Increased levels of gamma-glutamylamines in Huntington disease CSF","volume":"106","author":"Jeitner","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/s00726-011-1209-3","article-title":"gamma-Glutamylamines and neurodegenerative diseases","author":"Jeitner","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0150","doi-asserted-by":"crossref","first-page":"14580","DOI":"10.1073\/pnas.93.25.14580","article-title":"Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system","volume":"93","author":"Kahlem","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0155","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1097-2765(00)80059-3","article-title":"Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine","volume":"1","author":"Kahlem","year":"1998","journal-title":"Mol. Cell."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0160","first-page":"681","article-title":"Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion","volume":"46","author":"Kahlem","year":"1998","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0170","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1523\/JNEUROSCI.20-19-07268.2000","article-title":"Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy","volume":"20","author":"Kegel","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0175","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s11064-005-8796-x","article-title":"Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain","volume":"30","author":"Kim","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0180","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1046\/j.1471-4159.2003.02249.x","article-title":"Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats","volume":"88","author":"Lai","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0185","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1046\/j.1471-4159.1999.02018.x","article-title":"Tissue transglutaminase is increased in Huntington's disease brain","volume":"73","author":"Lesort","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0301-0082(99)00052-0","article-title":"Tissue transglutaminase: a possible role in neurodegenerative diseases","volume":"61","author":"Lesort","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0195","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1046\/j.1471-4159.2000.0751951.x","article-title":"Impaired mitochondrial function results in increased tissue transglutaminase activity in situ","volume":"75","author":"Lesort","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0200","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1074\/jbc.M205812200","article-title":"Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders","volume":"278","author":"Lesort","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00240602","article-title":"Transglutaminases","volume":"58","author":"Lorand","year":"1984","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0210","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrm1014","article-title":"Transglutaminases: crosslinking enzymes with pleiotropic functions","volume":"4","author":"Lorand","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0215","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0220","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","article-title":"Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: parallel changes in muscle and brain","volume":"11","author":"Luthi-Carter","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0225","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/11.17.1927","article-title":"Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects","volume":"11","author":"Luthi-Carter","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1212\/WNL.0b013e3181b04aa2","article-title":"Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants","volume":"73","author":"Marder","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0240","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401093","article-title":"\u2018Tissue\u2019 transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease","volume":"9","author":"Mastroberardino","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0245","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/emmm.201000084","article-title":"Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease","volume":"2","author":"McConoughey","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0250","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nbd.2008.11.015","article-title":"Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6\/2 mice","volume":"33","author":"Morton","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0255","first-page":"159","article-title":"A test to estimate VO2max in females using aerobic dance, heart rate, BMI, and age","volume":"35","author":"Olson","year":"1995","journal-title":"J. Sports Med. Phys. Fitness"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0260","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1749-6632.1999.tb07856.x","article-title":"Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease","volume":"893","author":"Panov","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0265","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/WNL.32.4.354","article-title":"A double-blind clinical trial of isoniazid in Huntington disease","volume":"32","author":"Perry","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0270","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1093\/hmg\/ddq247","article-title":"Mitochondrial calcium uptake capacity as a therapeutic target in the R6\/2 mouse model of Huntington's disease","volume":"19","author":"Perry","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0275","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03255.x","article-title":"Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease","volume":"94","author":"Pinto","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0285","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.58.5.695","article-title":"Regional and progressive thinning of the cortical ribbon in Huntington's disease","volume":"58","author":"Rosas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0290","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0295","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1602\/neurorx.1.2.263","article-title":"Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease","volume":"1","author":"Rosas","year":"2004","journal-title":"NeuroRx"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0300","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.neuroimage.2009.10.015","article-title":"Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical \u201cdisconnection\u201d","volume":"49","author":"Rosas","year":"2010","journal-title":"NeuroImage"},{"issue":"5","key":"10.1016\/j.expneurol.2012.05.015_bb0305","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00726-011-0899-x","article-title":"TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy","volume":"42","author":"Rossin","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0310","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.expneurol.2010.07.015","article-title":"Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6\/2 model of Huntington disease","volume":"225","author":"Tallaksen-Greene","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0315","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0320","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0325","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1471-4159.2006.03780.x","article-title":"Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage","volume":"97","author":"Tucholski","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0330","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0335","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2012.05.015_bb0340","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1126\/science.2841762","article-title":"NMDA receptor losses in putamen from patients with Huntington's disease","volume":"241","author":"Young","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2012.05.015_bb0345","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1074\/jbc.273.4.2288","article-title":"Modulation of the in situ activity of tissue transglutaminase by calcium and GTP","volume":"273","author":"Zhang","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"Pt 3","key":"10.1016\/j.expneurol.2012.05.015_bb0350","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1042\/0264-6021:3430541","article-title":"Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling","volume":"343","author":"Zhang","year":"1999","journal-title":"Biochem. J."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488612002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488612002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:51:10Z","timestamp":1714035070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488612002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0014488612002269"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2012.05.015","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}